Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2

Background. Hepatocellular carcinoma (HCC) is a severe global health issue that still lacks of effective treatments. Lenvatinib is a novel tyrosine kinase inhibitor (TKI) that has been approved for the treatment of HCC. However, drug resistance is inevitable and limits the clinical application of le...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Anqi, Li, Hui, Yu, Wenlong, Zhang, Yongjie, Yin, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596241/
https://www.ncbi.nlm.nih.gov/pubmed/36304988
http://dx.doi.org/10.1155/2022/4537343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596241/
https://www.ncbi.nlm.nih.gov/pubmed/36304988
http://dx.doi.org/10.1155/2022/4537343

Ejemplares similares